Influenza and pneumococcal vaccinations of patients with systemic lupus erythematosus: Current views upon safety and immunogenicity

Autoimmunity Reviews

Volumn 13, Issue 2, 2014, Pages 75-84

  Murdaca, Giuseppe ^a   Orsi, Andrea ^b   Spanò, Francesca ^a   Puppo, Francesco ^a   Durando, Paolo ^b   Icardi, Giancarlo ^b   Ansaldi, Filippo ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Influenza vaccine; Pneumococcal vaccine; Systemic lupus erythematosus

Indexed keywords

AUTOANTIBODY; BELIMUMAB; BETA DEFENSIN; BLOOD GROUP B ANTIGEN; CORTICOSTEROID; CYCLOSPORIN A; CYTOKINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GAMMA INTERFERON; GLUCOCORTICOID; HEMAGGLUTININ; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; INFLUENZA VACCINE; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 22; METHOTREXATE; PNEUMOCOCCUS POLYSACCHARIDE; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; RITUXIMAB; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VIRUS VACCINE;

ANAPHYLAXIS; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; FEVER; GENETIC REASSORTMENT; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INFLUENZA; INFLUENZA VACCINATION; INJECTION SITE PAIN; INJECTION SITE SWELLING; IRRITABILITY; NONHUMAN; PNEUMOCOCCAL INFECTION; REVIEW; SIDE EFFECT; STREPTOCOCCUS PNEUMONIAE; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE;

INFLUENZA VACCINE; PNEUMOCOCCAL VACCINE; SYSTEMIC LUPUS ERYTHEMATOSUS;

HUMANS; IMMUNOCOMPROMISED HOST; INFLUENZA VACCINES; INFLUENZA, HUMAN; LUPUS ERYTHEMATOSUS, SYSTEMIC; PNEUMOCOCCAL VACCINES; PRACTICE GUIDELINES AS TOPIC;

EID: 84888002219     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2013.07.007     Document Type: Review

References (143)

1. Abu-Shakra M., Press J., Buskila D., Sukenik S. Influenza vaccination of patients with systemic lupus erythematosus: safety and immunogenicity issues. Autoimmun Rev 2007, 6(8):543-546.
2. Murdaca G., Colombo B.M., Puppo F. Emerging biological drugs: a new therapeutic approach for systemic lupus erythematosus. An update upon efficacy and adverse events. Autoimmun Rev 2011, 11(1):56-60.
3. Campar A., Farinha F., Vasconcelos C. Refractory disease in systemic lupus erythematosus. Autoimmun Rev 2011, 10(11):685-692.
4. Arnaud L., Zahr N., Costedoat-Chalumeau N., Amoura Z. The importance of assessing medication exposure to the definition of refractory disease in systemic lupus erythematosus. Autoimmun Rev 2011 Sep, 10(11):674-678.
5. Looney R.J., Anolik J., Sanz I. B cells as therapeutic targets for rheumatic diseases. Curr Opin Rheumatol 2004, 16:180-185.
6. Anolik J.H., Aringer M. New treatments for SLE: cell-depleting and anti-cytokine therapies. Best Pract Res Clin Rheumatol 2005, 19:859-878.
7. Mount G.R., Gilliland W.R. Emerging biological therapies in systemic lupus erythematosus. Clin Pharmacol Ther 2008, 83:167-171.
8. Picchianti Diamanti A., Rosado M.M., Carsetti R., Valesini G. B cells in SLE: different biological drugs for different pathogenic mechanisms. Autoimmun Rev 2007, 7:143-148.
9. Guzman Moreno R. B-cell depletion in autoimmune diseases. Advances in autoimmunity. Autoimmun Rev 2009, 8:585-590.
10. Dong W., Zhu P., Wang Y., Wang Z. Follicular helper T cells in systemic lupus erythematosus: a potential therapeutic target. Autoimmun Rev 2011, 10:299-304.
11. Rahman A., Isenberg D.A. Systemic lupus erythematosus. N Engl J Med 2008, 358:929-939.
12. Meroni P.L., Shoenfeld Y. Systemic lupus erythematosus and the SLE galaxy. Autoimmun Rev 2010, 10:1-2.
13. Leng R.X., Pan H.F., Chen G.M., Feng C.C., Fan Y.G., Ye D.Q., et al. The dual nature of Ets-1: focus to the pathogenesis of systemic lupus erythematosus. Autoimmun Rev 2011, 10:439-443.
14. Crispín J.C., Liossis S.N., Kis-Toth K., Lieberman L.A., Kyttaris V.C., Juang Y.T., et al. Pathogenesis of human systemic lupus erythematosus: recent advances. Trends Mol Med 2010, 16:47-57.
15. Molina V., Shoenfeld Y. Infection, vaccines and other environmental triggers of autoimmunity. Autoimmunity 2005, 38(3):235-245.
16. Abu-Shakra M., Urowitz M.B., Gladman D.D., Gough J. Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. J Rheumatol 1995, 22(7):1259-1264.
17. Murdaca G., Colombo B.M., Cagnati P., Gulli R., Spanò F., Puppo F. Expert Opin Drug Saf 2012, 11(1):1-5.
18. Murdaca G., Colombo B.M., Puppo F. Adalimumab for the treatment of immune-mediated diseases: an update on old and recent indications. Drugs Today (Barc) 2011, 47(4):277-288.
19. Murdaca G., Colombo B.M., Puppo F. Anti-TNF-alpha inhibitors: a new therapeutic approach for inflammatory immune-mediated diseases: an update upon efficacy and adverse events. Int J Immunopathol Pharmacol 2009, 22(3):557-565.
20. Murdaca G., Colombo B.M., Barabino G., Caiti M., Cagnati P., Puppo F. Anti-tumor necrosis factor-α treatment with infliximab for disseminated granuloma annulare. Am J Clin Dermatol 2010, 11(6):437-439.
21. Puppo F., Murdaca G., Ghio M., Indiveri F. Emerging biologic drugs for the treatment of rheumatoid arthritis. Autoimmun Rev 2005, 4(8):537-541.
22. Bernatsky S., Hudson M., Suissa S. Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology 2007, 46:1157-1160.
23. Glück T., Kiefmann B., Grohmann M., Falk W., Straub R.H., Schölmerich J. Immune status and risk for infection in patients receiving chronic immunosuppressive therapy. J Rheumatol 2005, 32:1473-1480.
24. Allison A.C. Immunosuppressive drugs: the first 50years and a glance forward. Immunopharmacology 2000, 47:63-83.
25. van Assen S., Elkayam O., Agmon-Levin N., Cervera R., Doran M.F., Dougados M., et al. Vaccination in adult patients with auto-immune inflammatory rheumatic diseases: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for vaccination in adult patients with auto-immune inflammatory rheumatic diseases. Autoimmun Rev 2011, 10(6):341-352.
26. Wotton C.J., Goldacre M.J. Risk of invasive pneumococcal disease in people admitted to hospital with selected immune-mediated diseases: record linkage cohort analyses. J Epidemiol Community Health 2012, 66(12):1177-1181.
27. Nicholson K.G., Wood J.M., Zambon M. Influenza. Lancet 2003, 362:1733-1745.
28. van Assen S., Agmon-Levin N., Elkayam O., Cervera R., Doran M.F., Dougados M., et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2011, 70:414-422.
29. Lanternier F., Henegar C., Mouthon L., Blanche P., Guillevin L., Launay O. Low influenza-vaccination rate among adults receiving immunosuppressive therapy for systemic inflammatory disease. Ann Rheum Dis 2008, 67:1047.
30. Conti F., Rezai S., Valesini G. Vaccination and autoimmune rheumatic diseases. Autoimmun Rev 2008, 8:124-128.
31. Elkayam O. Safety and efficacy of vaccination against influenza in patients with rheumatoid arthritis. Clin Dev Immunol 2006, 13:349-351.
32. Cox N.J., Subbarao K. Influenza. Lancet 1999, 354:1277-1282.
33. Centers for Disease Control, Prevention (CDC) Swine influenza A (A/H1N1) infection in two children-Southern California, March-April 2009. MMWR Morb Mortal Wkly Rep 2009, 58:400-402.
34. Garten R.J., Davis C.T., Russell C.A., Shu B., Lindstrom S., Balish A., et al. Antigenic and genetic characteristics of swine-origin 2009 A(A/H1N1) influenza viruses circulating in humans. Science 2009, 325:197-201.
35. World Health Organization New influenza A (A/H1N1) virus: global epidemiological situation, June 2009. Wkly Epidemiol Rec 2009, 84:249-257.
36. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980, 23:58-59.
37. Kumar A., Zarychanski R., Pinto R., Cook D.J., Marshall J., Lacroix J., et al. Critically ill patients with 2009 influenza A(A/H1N1) infection in Canada. JAMA 2009, 302:1872-1879.
38. Webb S.A., Pettilä V., Seppelt I., Bellomo R., Bailey M., Cooper D.J., et al. Critical care services and 2009 A/H1N1 influenza in Australia and New Zealand. N Engl J Med 2009, 361:1925-1934. ANZIC Influenza Investigators.
39. Jain S., Kamimoto L., Bramley A.M., Schmitz A.M., Benoit S.R., Louie J., et al. Hospitalized patients with 2009 A/H1N1 influenza in the United States, April-June 2009. N Engl J Med 2009, 361:1935-1944.
40. Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team, Dawood F.S., Jain S., Finelli L., Shaw M.W., Lindstrom S., Garten R.J., et al. Emergence of a novel swine-origin influenza A (A/H1N1) virus in humans. N Engl J Med 2009, 360:2605-2615.
41. Centers for Disease Control and Prevention (CDC). Intensive-care patients with severe novel influenza A(A/H1N1) virus infection-Michigan, June 2009. MMWR Morb Mortal Wkly Rep 2009, 58:749-752.
42. Arom-Maor A., Shoenfeld Y. Vaccination and systemic lupus erythematosus: the bidirectional dilemmas. Lupus 2001, 10:237-240.
43. Holvast B., Huckriede A., Kallenberg C.G., Bijl M. Influenza vaccination in systemic lupus erythematosus: safe and protective?. Autoimmun Rev 2007, 6(5):300-305.
44. Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)-United States, 2012-13 influenza season. MMWR Morb Mortal Wkly Rep 2012, 61(32):613-618.
45. Food and Drug Administration Summary minutes: Vaccines and Related Biological Products Advisory Committee, February 28-29, 2012 2012, US Department of Health and Human Services, Food and Drug Administration, Silver Spring, MD, [Available at http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/bloodvaccinesandotherbiologics/vaccinesandrelatedbiologicalproductsadvisorycommittee/ucm296193.pdf. Accessed August 10, 2012].
46. Herron A., Dettleff G., Hixon B., Brandwin L., Ortbals D., Hornick R., et al. Influenza vaccination in patients with rheumatic diseases. Safety and efficacy. JAMA 1979, 242(1):53-56.
47. Perdan-Pirkmajer K., Thallinger G.G., Snoj N., Cucnik S., Zigon P., Kveder T., et al. Autoimmune response following influenza vaccination in patients with autoimmune inflammatory rheumatic disease. Lupus 2012, 21:175-183.
48. Abu-Shakra M., Press J., Sukenik S., Buskila D. Influenza virus vaccination of patients with SLE: effects on generation of autoantibodies. Clin Rheumatol 2002, 21(5):369-372.
49. Abu-Shakra M., Zalmanson S., Neumann L., Flusser D., Sukenik S., Buskila D. Influenza virus vaccination of patients with systemic lupus erythematosus: effects on disease activity. J Rheumatol 2000, 27(7):1681-1685.
50. Older S.A., Battafarano D.F., Enzenauer R.J., Krieg A.M. Can immunization precipitate connective tissue disease? Report of five cases of systemic lupus erythematosus and review of the literature. Semin Arthritis Rheum Dec 1999, 29(3):131-139.
51. Vista E.S., Crowe S.R., Thompson L.F., Air G.M., Robertson J.M., Guthridge J.M., et al. Influenza vaccination can induce new-onset anticardiolipins but not β2-glycoprotein-I antibodies among patients with systemic lupus erythematosus. Lupus 2012, 21:168-174.
52. Williams G.W., Steinberg A.D., Reinertsen J.L., Klassen L.W., Decker J.L., Dolin R. Influenza immunization in systemic lupus erythematosus. A double-blind trial. Ann Intern Med 1978, 88(6):729-734.
53. Ristow S.C., Gouglas G., Condemi J.J. Influenza vaccination of patients with systemic lupus erythematosus. Ann Intern Med 1978, 88(6):786-789.
54. Abu-Shakra M., Press J., Varsano N., Levy V., Mendelson E., Sukenik S., et al. Specific antibody response after influenza immunization in systemic lupus erythematosus. J Rheumatol 2002, 29(12):2555-2557.
55. Gross P.A., Hermogenes A.W., SacksHS Lau J., Levandowski R.A. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med 1995, 123(7):518-527.
56. De Jong J.C., Palache A.M., Beyer W.E., Rimmelzwaan G.F., Boon A.C., Osterhaus A.D. Haemagglutination-inhibiting antibody to influenza virus. Dev Biol (Basel) 2003, 115:63-73.
57. Holvast A., Huckriede A., Wilschut J., Horst G., De Vries J.J., Benne C.A., et al. Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease. Ann Rheum Dis 2006, 65(7):913-918.
58. Mercado U., Acosta H., Avendano L. Influenza vaccination of patients with systemic lupus erythematosus. Rev Invest Clin 2004, 56(1):16-20.
59. Wiesik-Szewczyk E., Romanowska M., Mielnik P., Chwalińska-Sadowska H., Brydak L.B., Olesińska M., et al. Anti-influenza vaccination in systemic lupus erythematosus patients: an analysis of specific humoral response and vaccination safety. Clin Rheumatol 2010, 29(6):605-613.
60. Del Porto F., Laganà B., Biselli R., Donatelli I., Campitelli L., Nisini R., et al. Influenza vaccine administration in patients with systemic lupus erythematosus and rheumatoid arthritis Safety and immunogenicity. Vaccine 2006, 24(16):3217-3223.
61. Holvast A., van Assen S., de Haan A., Huckriede A., Benne C.A., Westra J., et al. Effect of a second, booster, influenza vaccination on antibody responses in quiescent systemic lupus erythematosus: an open, prospective, controlled study. Rheumatology (Oxford) 2009, 48:1294-1299.
62. European Medicines Agency (EMEA). Note for guidance on harmonisation of requirements for influenza vaccines 1997, [CPMP/BWP/214/96].
63. Heijstek M.W., de Bruin LM Ott, Borrow R., van der Klis F., Koné-Paut I., Fasth A., et al. Vaccination in paediatric patients with auto-immune rheumatic diseases: a systemic literature review for the European League against Rheumatism evidence-based recommendations. Autoimmun Rev 2011, 11(2):112-122.
64. Bijl M., Agmon-Levin N., Dayer J.M., Israeli E., Gatto M., Shoenfeld Y. Vaccination of patients with auto-immune inflammatory rheumatic diseases requires careful benefit-risk assessment. Autoimmun Rev 2012, 11(8):572-576.
65. Saad C.G., Borba E.F., Aikawa N.E., Silva C.A., Pereira R.M., Calich A.L., et al. Immunogenicity and safety of the 2009 non-adjuvanted influenza A/H1N1 vaccine in a large cohort of autoimmune rheumatic diseases. Ann Rheum Dis 2011, 70:1068-1073.
66. Agmon-Levin N., Paz Z., Israeli E., Shoenfeld Y., et al. Vaccines and autoimmunity. Nat Rev Rheumatol 2009, 5:648-652.
67. Shoenfeld Y., Agmon-Levin N. 'ASIA'-autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun 2011, 36:4-8.
68. Agmon-Levin N., Hughes G.R.V., Shoenfeld Y. The spectrum of ASIA: 'Autoimmune (Auto-inflammatory) Syndrome induced by Adjuvants'. Lupus 2012, 21:118-120.
69. Jara L.J., Medina G., Gómez-Bañuelos E., Saavedra M.A., Vera-Lastra O. Still's disease, lupus-like syndrome, and silicone breast implants. A case of 'ASIA' (Shoenfeld's syndrome). Lupus 2012, 21:140-145.
70. Zafrir Y., Agmon-Levin N., Paz Z., Shilton T., Shoenfeld Y. Autoimmunity following Hepatitis B vaccine as part of the spectrum of 'Autoimmune (Auto-inflammatory) Syndrome induced by Adjuvants' (ASIA): analysis of 93 cases. Lupus 2012, 21:146-152.
71. Bassi N., Luisetto R., Del Prete D., Ghirardello A., Ceol M., Rizzo S., et al. Induction of the 'ASIA' syndrome in NZB/NZWF1 mice after injection of complete Freund's adjuvant (CFA). Lupus 2012, 21:203-209.
72. Conti F., Rezai S., Valesini G. Vaccination and autoimmune rheumatic diseases. Autoimmun Rev 2008, 8:124-128.
73. Salemi S., Picchianti-Diamanti A., Germano V., Donatelli I., Di Martino A., Facchini M., et al. Influenza vaccine administration in rheumatoid arthritis patients under treatment with TNFalpha blockers: safety and immunogenicity. Clin Immunol 2010, 134:113-120.
74. Bingham C.O., Looney R.J., Deodhar A., Halsey N., Greenwald M., Codding C., et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum 2010, 62:64-74.
75. van Assen S., Holvast A., Benne C.A., Posthumus M.D., van Leeuwen M.A., Voskuyl A.E., et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 2010, 62:75-81.
76. Gelinck L.B., van der Bijl A.E., Beyer W.E., Visser L.G., Huizinga T.W., van Hogezand R.A., et al. The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination. Ann Rheum Dis 2008, 67:713-716.
77. Elkayam O., Bashkin A., Mandelboim M., et al. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum 2010, 39:442-447.
78. Lu C.C., Wang Y.C., Lai J.H., Lee T.S., LIN H.T., Chang D.M. A/H1N1 influenza vaccination in patients with systemic lupus erythematosus: safety and immunity. Vaccine 2011, 29(3):444-450.
79. Borba E.F., Saad C.G., Pasoto S.G., Calich A.L., Aikawa N.E., Ribeiro A.C., et al. Influenza A/H1N1 vaccination of patients with SLE: can antimalarial drugs restore diminished response under immunosuppressive therapy?. Rheumatology (Oxford) Jun 2012, 51(6):1061.
80. Chatham W.W., Wallace D.J., Stohl W., Latinis K.M., Manzi S., McCune W.J., et al. Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial. BLISS-76 Study Group. J Rheumatol Aug 2012, 39(8):1632-1640.
81. Lu Y., Jacobson D.L., Ashworth L.A., Grand R.J., Meyer A.L., McNeal M.M., et al. Immune response to influenza vaccine in children with inflammatory bowel disease. Am J Gastroenterol 2009, 104(2):444-453.
82. Crowe S.R., Merrill J.T., Vista E.S., Dedeke A.B., Thompson D.M., Stewart S., et al. Influenza vaccination responses in human systemic lupus erythematosus: impact of clinical and demographic features. Arthritis Rheum 2011, 63(8):2396-2406.
83. Murdaca G., Colombo B.M., Puppo F. The role of Th17 lymphocytes in the autoimmune and chronic inflammatory diseases. Intern Emerg Med 2011, 6(6):487-495.
84. Ouyang W., Kolls J.K., Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 2008, 28(4):454-467.
85. Liang S.C., Tan X.Y., Luxenberg D.P., Karim R., Dunussi-Joannopoulos K., Collins M., et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 2006, 203:2271-2279.
86. Rosenkrands I., Vingsbo-Lundberg C., Bundgaard T.J., Lindenstrøm T., Enouf V., van der Werf S., et al. Enhanced humoral and cell-mediated immune responses after immunization with trivalent influenza vaccine adjuvanted with cationic liposomes. Vaccine 2011, 29(37):6283-6291.
87. McElhaney J.E., Ewen C., Zhou X., et al. Granzyme B: correlates with protection and enhanced CTL response to influenza vaccination in older adults. Vaccine 2009, 27:2418-2425.
88. Thomas P.G., Keating R., Hulse-Post D.J., Doherty P.C. Cell-mediated protection in influenza infection. Emerg Infect Dis 2006, 12:48-54.
89. Forrest B.D., Pride M.W., Dunning A.J., Capeding M.R., Chotpitayasunondh T., Tam J.S., et al. Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin Vaccine Immunol 2008, 15:1042-1053.
90. McElhaney J.E., Xie D., Hager W.D., Barry M.B., Wang Y., Kleppinger A., et al. T cell responses are better correlates of vaccine protection in the elderly. J Immunol 2006, 176:6333-6339.
91. Holvast A., van Assen S., de Haan A., Huckriede A., Benne C.A., Westra J., et al. Studies of cell-mediated immune responses to influenza vaccination in systemic lupus erythematosus. Arthritis Rheum 2009, 60:2438-2447.
92. Bermas B.L., Petri M., Goldman D., Mittleman B., Miller M.W., Stocks N.I., et al. T helper cell dysfunction in systemic lupus erythematosus (SLE): relation to disease activity. J Clin Immunol 1994, 14(3):169-177.
93. Grondal G., Gunnarsson I., Ronnelid J., Rogberg S., Klareskog L., Lundberg I. Cytokine production, serum levels and disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 2000, 18(5):565-570.
94. Huckriede A., Bungener L., Stegmann T., Daemen T., Medema J., Palache A.M., et al. The virosome concept for influenza vaccines. Vaccine 2005, 23(Suppl. 1):S26-S38.
95. Tudela P., Marti S., Bonal J. SLE and vaccination against hepatitis B. Nephron 1992, 62:236-237.
96. Ayvazian L.F., Badger T.L. Disseminated lupus erythematosus occurring among student nurses. N Engl J Med 1948, 239:565-570.
97. Hurwitz E.S., Sconberger L.B., Nelson D.B., Holman R.C. Guillain Barre syndrome and the 1978-1979 influenza vaccine. N Engl J Med 1981, 304:1557-1561.
98. Hess E.V., Hahn B. Influenza immunization in lupus erythematosus: safe, effective?. Ann Intern Med 1978, 88:833-834.
99. Brodman R., Gilfillan R., Glass D., Schur P.H. Influenzal vaccine response in systemic lupus erythematosus. Ann Intern Med 1978, 88(6):735-740.
100. Louie J.S., Nies K.M., Shoji K.T., Fraback R.C., Abrass C., Border W., et al. Clinical and antibody responses after influenza immunization in systemic lupus erythematosus. Ann Intern Med 1978, 88(6):790-792.
101. Stojanovich L. Influenza vaccination of patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Clin Dev Immunol 2006, 13(2-4):373-375.
102. Vila-Córcoles A. Vaccinate your child and save its grandparents from a heart attack? Current perspectives in antipneumococcal vaccination. J Intern Med 2009, 266(5):432-444.
103. Glück T., Müller-Ladner U. Vaccination in patients with chronic rheumatic or autoimmune diseases. Clin Infect Dis 2008, 46(9):1459-1465.
104. Ortqvist A., Hedlund J., Kalin M. Streptococcus pneumoniae: epidemiology, risk factors, and clinical features. Semin Respir Crit Care Med 2005, 26:563-574.
105. Hausdorff W.P., Feikin D.R., Klugman K.P. Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis 2005, 5:83-93.
106. Weinberger D.M., Harboe Z.B., Sanders E.A.M., Ndiritu M., Klugman K.P., Ruckinger S., et al. Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis. Clin Infect Dis 2010, 51:692-699.
107. Abeyta M., Hardy G.G., Yother J. Genetic alteration of capsule type but not PspA type affects accessibility of surface-bound complement and surface antigens of Streptococcus pneumoniae. Infect Immun 2003, 71:218-225.
108. Wartha F., Beiter K., Albiger B., Fernebro J., Zychlinsky A., Normark S., et al. Capsule and D-alanylated lipoteichoic acids protect Streptococcus pneumoniae against neutrophil extracellular traps. Cell Microbiol 2007, 9:1162-1171.
109. Hyams C., Camberlein E., Cohen J.M., Bax K., Brown J.S. The Streptococcus pneumoniae capsule inhibits complement activity and neutrophil phagocytosis by multiple mechanisms. Infect Immun 2010, 78:704-715.
110. Kadioglu A., Taylor S., Iannelli F., Pozzi G., Mitchell T.J., Andrew P.W. Upper and lower respiratory tract infection by Streptococcus pneumoniae is affected by pneumolysin deficiency and differences in capsule type. Infect Immun 2002, 70:2886-2890.
111. Witzenrath M., Gutbier B., Hocke A.C., Schmeck B., Hippenstiel S., Berger K., et al. Role of pneumolysin for the development of acute lung injury in pneumococcal pneumonia. Crit Care Med 2006, 34:1947-1954.
112. Hirst R.A., Gosai B., Rutman A., Guerin C.J., Nicotera P., Andrew P.W., et al. Streptococcus pneumoniae deficient in pneumolysin or autolysin has reduced virulence in meningitis. J Infect Dis 2008, 197:744-751.
113. Karlstrom A., Heston S.M., Boyd K.L., Tuomanen E., McCullers J.A. Toll-like receptor 2 mediates fatal immunopathology in mice during treatment of secondary pneumococcal pneumonia following influenza. J Infect Dis 2011, 204:1358-1366.
114. Vance R.E., Isberg R.R., Portnoy D.A. Patterns of pathogenesis: discrimination of pathogenic and nonpathogenic microbes by the innate immune system. Cell Host Microbe 2009, 6:10-21.
115. Moens L., Wuyts G., Boon L., den Hartog M.T., Ceuppens J.L., Bossuyt X. The human polysaccharide- and protein-specific immune response to Streptococcus pneumoniae is dependent on CD4(+) T lymphocytes, CD14(+) monocytes, and the CD40-CD40 ligand interaction. J Allergy Clin Immunol 2008, 122(6):1231-1233.
116. Fedson D.S., Musher D.M. Pneumococcal polysaccharide vaccine 2003, 529-588. Saunders, Philadelphia. S.A. Plotkin, W.A. Orenstein (Eds.).
117. Tan T.Q. Pediatric invasive pneumococcal disease in the United States in the era of pneumococcal conjugate vaccines. Clin Microbiol Rev 2012, 25(3):409-419.
118. American Academy of Pediatrics Committee on Infectious Diseases Recommendations for the prevention of pneumococcal infections, including use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics 2000, 106:362-366.
119. Centers for Disease Control, Prevention Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children. MMWR Morb Mortal Wkly Rep 2010, 59:258-261.
120. Klippel J.H., Karsh J., Stahl N.I., Decker J.L., Steinberg A.D., Schiffman G. A controlled study of pneumococcal polysaccharide vaccine in systemic lupus erythematosus. Arthritis Rheum 1979, 22:1321-1325.
121. Karsh J., Pavlidis N., Schiffman G., Moutsopoulos H.M. Immunization of patients with Sjögren's syndrome with pneumococcal polysaccharide vaccine: a randomized trial. Arthritis Rheum 1980, 23:1294-1298.
122. Jarrett M.P., Schiffman G., Barland P., Grayzel A.I. Impaired response to pneumococcal vaccine in systemic lupus erythematosus. Arthritis Rheum 1980, 23:1287-1293.
123. Lipnick R.N., Karsh J., Stahl N.I., Blackwelder W.C., Schiffman G., Klippel J.H. Pneumococcal immunization in patients with systemic lupus erythematosus treated with immunosuppressives. J Rheumatol 1985, 12:1118-1121.
124. Battafarano D.F., Battafarano N.J., Larsen L., Dyer P.D., Older S.A., Muehlbauer S., et al. Antigen-specific antibody responses in lupus patients following immunization. Arthritis Rheum 1998, 41:1828-1834.
125. Elkayam O., Paran D., Caspi D., Litinsky I., Yaron M., Charboneau D., et al. Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus. Clin Infect Dis 2002, 34:147-153.
126. De Roux Schmidt N., Rose M., Zielen S., Pletz M., Lode H. Immunogenicity of the pneumococcal polysaccharide vaccine in COPD patients: the effect of systemic steroids. Respir Med 2004, 98:1187-1194.
127. Dengler T.J., Strnad N., Bühring I., Zimmermann R., Girgsdies O., Kubler W.E., et al. Differential immune response to influenza and pneumococcal vaccination in immunosuppressed patients after heart transplantation. Transplantation 1998, 66:1340-1347.
128. Elkayam O., Caspi D., Reitblatt T., Charboneau D., Rubins J.B. The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum 2004, 33:283-288.
129. Kapetanovic M.C., Saxne T., Sjöholm A., Truedsson L., Jönsson G., Geborek P. Influence of methotrexate, TNF-blockers and prednisolone on antibody responses to pneumococcal vaccine in patients with rheumatoid arthritis. Rheumatology 2006, 45:106-111.
130. Pisoni C., Sarano J., Benchetrit G., Rodríguez D., Suárez L., Perrota C., et al. Antipneumococcal vaccination in patient with systemic lupus erythematosus. Medicina (B Aires) 2003, 63(5):388-392.
131. McDonald E., Jarrett M.P., Schiffman G., Grayzel A.I. Persistence of pneumococcal antibodies after immunization in patients with systemic lupus erythematosus. J Rheumatol 1984, 11:306-308.
132. Meisel R., Kuypers L., Dirksen U., Schubert R., Gruhn B., Strauss G., et al. Pneumococcal conjugate vaccine provides early protective antibody responses in children after related and unrelated allogeneic hematopoietic stem cell transplantation. Blood 2007, 109:2322-2326.
133. Kadioglu A., Coward W., Colston M.J., Hewitt C.R., Andrew P.W. CD4-T-lymphocyte interactions with pneumolysin and pneumococci suggest a crucial protective role in the host response to pneumococcal infection. Infect Immun 2004, 72:2689-2697.
134. Trzcinski K., Thompson C.M., Srivastava A., Basset A., Malley R., Lipsitch M. Protection against nasopharyngeal colonization by Streptococcus pneumoniae is mediated by antigen-specific CD4+ T cells. Infect Immun 2008, 76:2678-84.+.
135. Malley R., Trzcinski K., Srivastava A., Thompson C.M., Anderson P.W., Lipsitch M. CD4+ T cells mediate antibody-independent acquired immunity to pneumococcal colonization. Proc Natl Acad Sci U S A 2005, 102:4848-4853.
136. Trzcinski K., Thompson C., Malley R., Lipsitch M. Antibodies to conserved pneumococcal antigens correlate with, but are not required for, protection against pneumococcal colonization induced by prior exposure in a mouse model. Infect Immun 2005, 73:7043-7046.
137. Gentile A., Bazán V. Prevention of pneumococcal disease through vaccination. Vaccine 2011, 29(Suppl. 3):C15-C25.
138. Baril L., Dietemann J., Essevaz-Roulet M., Béniguel L., Coan P., Briles D.E., et al. Pneumococcal surface protein A (PspA) is effective at eliciting T cell-mediated responses during invasive pneumococcal disease in adults. Clin Exp Immunol 2006, 145(2):277-286.
139. Mureithi M.W., Finn A., Ota M.O., Zhang Q., Davenport V., Mitchell T.J., et al. T cell memory response to pneumococcal protein antigens in an area of high pneumococcal carriage and disease. J Infect Dis 2009, 200(5):783-793.
140. Lundgren A., Bhuiyan T.R., Novak D., Kaim J., Reske A., Lu Y.J., et al. Characterization of Th17 responses to Streptococcus pneumoniae in humans: comparisons between adults and children in a developed and a developing country. Vaccine 2012, 30(26):3897-3907.
141. Cohen J.M., Khandavilli S., Camberlein E., Hyams C., Baxendale H.E., Brown J.S. Protective contributions against invasive Streptococcus pneumoniae pneumonia of antibody and Th17-cell responses to nasopharyngeal colonisation. PLoS One 2011, 6(10):e25558.
142. Ponvert C., Ardelean-Jaby D., Colin-Gorski A.M., Soufflet B., Hamberger C., de Blic J., et al. Anaphylaxis to the 23-valent pneumococcal vaccine in child: a case-control study based on immediate responses in skin tests and specific IgE determination. Vaccine 2001, 19(32):4588-4591.
143. Elkayam O., Paran D., Burke M., Zakut V., Ben-Yitshak R., Litinsky I., et al. Pneumococcal vaccination of patients with systemic lupus erythematosus: effects on generation of autoantibodies. Autoimmunity 2005, 38(7):493-496.